Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
Titel:
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
Auteur:
Zhou, C. Wu, Y.L. Chen, G. Feng, J. Liu, X.-Q. Wang, C. Zhang, S. Wang, J. Zhou, S. Ren, S. Lu, S. Zhang, L. Hu, C. Hu, C. Luo, Y. Chen, L. Ye, M. Huang, J. Zhi, X. Zhang, Y. Xiu, Q. Ma, J. Zhang, L. You, C.